Cargando…

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

BACKGROUND: Patients treated with standard chemotherapy for metastatic or relapsed cervical cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of patients) with an overall survival of less than 1 year. High tumour angiogenesis and high concentrations of intratumoural VEG...

Descripción completa

Detalles Bibliográficos
Autores principales: Symonds, R Paul, Gourley, Charlie, Davidson, Susan, Carty, Karen, McCartney, Elaine, Rai, Debbie, Banerjee, Susana, Jackson, David, Lord, Rosemary, McCormack, Mary, Hudson, Emma, Reed, Nicholas, Flubacher, Maxine, Jankowska, Petra, Powell, Melanie, Dive, Caroline, West, Catharine M L, Paul, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705431/
https://www.ncbi.nlm.nih.gov/pubmed/26474517
http://dx.doi.org/10.1016/S1470-2045(15)00220-X
_version_ 1782409012153679872
author Symonds, R Paul
Gourley, Charlie
Davidson, Susan
Carty, Karen
McCartney, Elaine
Rai, Debbie
Banerjee, Susana
Jackson, David
Lord, Rosemary
McCormack, Mary
Hudson, Emma
Reed, Nicholas
Flubacher, Maxine
Jankowska, Petra
Powell, Melanie
Dive, Caroline
West, Catharine M L
Paul, James
author_facet Symonds, R Paul
Gourley, Charlie
Davidson, Susan
Carty, Karen
McCartney, Elaine
Rai, Debbie
Banerjee, Susana
Jackson, David
Lord, Rosemary
McCormack, Mary
Hudson, Emma
Reed, Nicholas
Flubacher, Maxine
Jankowska, Petra
Powell, Melanie
Dive, Caroline
West, Catharine M L
Paul, James
author_sort Symonds, R Paul
collection PubMed
description BACKGROUND: Patients treated with standard chemotherapy for metastatic or relapsed cervical cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of patients) with an overall survival of less than 1 year. High tumour angiogenesis and high concentrations of intratumoural VEGF are adverse prognostic features. Cediranib is a potent tyrosine kinase inhibitor of VEGFR1, 2, and 3. In this trial, we aimed to assess the effect of the addition of cediranib to carboplatin and paclitaxel chemotherapy in patients with metastatic or recurrent cervical cancer. METHODS: In this randomised, double-blind, placebo-controlled phase 2 trial, which was done in 17 UK cancer treatment centres, patients aged 18 years or older initially diagnosed with metastatic carcinoma or who subsequently developed metastatic disease or local pelvic recurrence after radical treatment that was not amenable to exenterative surgery were recruited. Eligible patients received carboplatin AUC of 5 plus paclitaxel 175 mg/m(2) by infusion every 3 weeks for a maximum of six cycles and were randomised centrally (1:1) through a minimisation approach to receive cediranib 20 mg or placebo orally once daily until disease progression. The stratification factors were disease site, disease-free survival after primary therapy or primary stage IVb disease, number of lines of previous treatment, Eastern Cooperative Oncology Group performance status, and investigational site. All patients, investigators, and trial personnel were masked to study drug allocation. The primary endpoint was progression-free survival. Efficacy analysis was by intention to treat, and the safety analysis included all patients who received at least one dose of study drug. This trial is registered with the ISCRTN registry, number ISRCTN23516549, and has been completed. FINDINGS: Between Aug 19, 2010, and July 27, 2012, 69 patients were enrolled and randomly assigned to cediranib (n=34) or placebo (n=35). After a median follow-up of 24·2 months (IQR 21·9–29·5), progression-free survival was longer in the cediranib group (median 8·1 months [80% CI 7·4–8·8]) than in the placebo group (6·7 months [6·2–7·2]), with a hazard ratio (HR) of 0·58 (80% CI 0·40–0·85; one-sided p=0·032). Grade 3 or worse adverse events that occurred in the concurrent chemotherapy and trial drug period in more than 10% of patients were diarrhoea (five [16%] of 32 patients in the cediranib group vs one [3%] of 35 patients in the placebo group), fatigue (four [13%] vs two [6%]), leucopenia (five [16%] vs three [9%]), neutropenia (10 [31%] vs four [11%]), and febrile neutropenia (five [16%] vs none). The incidence of grade 2–3 hypertension was higher in the cediranib group than in the control group (11 [34%] vs four [11%]). Serious adverse events occurred in 18 patients in the placebo group and 19 patients in the cediranib group. INTERPRETATION: Cediranib has significant efficacy when added to carboplatin and paclitaxel in the treatment of metastatic or recurrent cervical cancer. This finding was accompanied by an increase in toxic effects (mainly diarrhoea, hypertension, and febrile neutropenia). FUNDING: Cancer Research UK and AstraZeneca.
format Online
Article
Text
id pubmed-4705431
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lancet Pub. Group
record_format MEDLINE/PubMed
spelling pubmed-47054312016-02-08 Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial Symonds, R Paul Gourley, Charlie Davidson, Susan Carty, Karen McCartney, Elaine Rai, Debbie Banerjee, Susana Jackson, David Lord, Rosemary McCormack, Mary Hudson, Emma Reed, Nicholas Flubacher, Maxine Jankowska, Petra Powell, Melanie Dive, Caroline West, Catharine M L Paul, James Lancet Oncol Articles BACKGROUND: Patients treated with standard chemotherapy for metastatic or relapsed cervical cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of patients) with an overall survival of less than 1 year. High tumour angiogenesis and high concentrations of intratumoural VEGF are adverse prognostic features. Cediranib is a potent tyrosine kinase inhibitor of VEGFR1, 2, and 3. In this trial, we aimed to assess the effect of the addition of cediranib to carboplatin and paclitaxel chemotherapy in patients with metastatic or recurrent cervical cancer. METHODS: In this randomised, double-blind, placebo-controlled phase 2 trial, which was done in 17 UK cancer treatment centres, patients aged 18 years or older initially diagnosed with metastatic carcinoma or who subsequently developed metastatic disease or local pelvic recurrence after radical treatment that was not amenable to exenterative surgery were recruited. Eligible patients received carboplatin AUC of 5 plus paclitaxel 175 mg/m(2) by infusion every 3 weeks for a maximum of six cycles and were randomised centrally (1:1) through a minimisation approach to receive cediranib 20 mg or placebo orally once daily until disease progression. The stratification factors were disease site, disease-free survival after primary therapy or primary stage IVb disease, number of lines of previous treatment, Eastern Cooperative Oncology Group performance status, and investigational site. All patients, investigators, and trial personnel were masked to study drug allocation. The primary endpoint was progression-free survival. Efficacy analysis was by intention to treat, and the safety analysis included all patients who received at least one dose of study drug. This trial is registered with the ISCRTN registry, number ISRCTN23516549, and has been completed. FINDINGS: Between Aug 19, 2010, and July 27, 2012, 69 patients were enrolled and randomly assigned to cediranib (n=34) or placebo (n=35). After a median follow-up of 24·2 months (IQR 21·9–29·5), progression-free survival was longer in the cediranib group (median 8·1 months [80% CI 7·4–8·8]) than in the placebo group (6·7 months [6·2–7·2]), with a hazard ratio (HR) of 0·58 (80% CI 0·40–0·85; one-sided p=0·032). Grade 3 or worse adverse events that occurred in the concurrent chemotherapy and trial drug period in more than 10% of patients were diarrhoea (five [16%] of 32 patients in the cediranib group vs one [3%] of 35 patients in the placebo group), fatigue (four [13%] vs two [6%]), leucopenia (five [16%] vs three [9%]), neutropenia (10 [31%] vs four [11%]), and febrile neutropenia (five [16%] vs none). The incidence of grade 2–3 hypertension was higher in the cediranib group than in the control group (11 [34%] vs four [11%]). Serious adverse events occurred in 18 patients in the placebo group and 19 patients in the cediranib group. INTERPRETATION: Cediranib has significant efficacy when added to carboplatin and paclitaxel in the treatment of metastatic or recurrent cervical cancer. This finding was accompanied by an increase in toxic effects (mainly diarrhoea, hypertension, and febrile neutropenia). FUNDING: Cancer Research UK and AstraZeneca. Lancet Pub. Group 2015-11 /pmc/articles/PMC4705431/ /pubmed/26474517 http://dx.doi.org/10.1016/S1470-2045(15)00220-X Text en © 2015 Symonds et al. Open Access article distributed under the terms of CC BY http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Symonds, R Paul
Gourley, Charlie
Davidson, Susan
Carty, Karen
McCartney, Elaine
Rai, Debbie
Banerjee, Susana
Jackson, David
Lord, Rosemary
McCormack, Mary
Hudson, Emma
Reed, Nicholas
Flubacher, Maxine
Jankowska, Petra
Powell, Melanie
Dive, Caroline
West, Catharine M L
Paul, James
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
title Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
title_full Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
title_fullStr Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
title_full_unstemmed Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
title_short Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
title_sort cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (circca): a randomised, double-blind, placebo-controlled phase 2 trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705431/
https://www.ncbi.nlm.nih.gov/pubmed/26474517
http://dx.doi.org/10.1016/S1470-2045(15)00220-X
work_keys_str_mv AT symondsrpaul cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT gourleycharlie cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT davidsonsusan cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT cartykaren cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT mccartneyelaine cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT raidebbie cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT banerjeesusana cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT jacksondavid cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT lordrosemary cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT mccormackmary cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT hudsonemma cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT reednicholas cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT flubachermaxine cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT jankowskapetra cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT powellmelanie cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT divecaroline cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT westcatharineml cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial
AT pauljames cediranibcombinedwithcarboplatinandpaclitaxelinpatientswithmetastaticorrecurrentcervicalcancercirccaarandomiseddoubleblindplacebocontrolledphase2trial